The combination of dasatinib and the irreversible pan-HER TKI afatinib has been examined in a phase I clinical trial (NCT01999985) in a cohort of non-small cell lung cancer patients who had received at least two EGFR-targeting regimens, reporting that a pan-HER inhibitor and dasatinib was well-tolerated. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.